1557MO Phase II trial evaluating effect of gonyautoxins (GTX), a paralytic shellfish poisoning (PSP) on objective and subjective symptoms of chemotherapy-induced peripheral neuropathy (CIPN)

Abstract

CIPN is a common side-effect of anti-neoplastic drugs with no level 1 supportive treatment (Tx) approvals. Management of the adverse event (AE) is restricted to dose reductions and Tx interruptions. GTX is a PSP phycotoxin that reversibly binds voltage-gated sodium channel receptor sites on excitable cells, inhibiting membrane depolarization and nerve impulse conduction. Initial data indicates that GTX (topical formulation) improves PN-symptoms related to anti-HIV drugs. The aim of this study is to evaluate the effect of GTX on sensory symptoms of pts with grade 2 or higher (G≥2) CIPN.